- Home
- SMG vs TNGX Comparison
SMG vs TNGX Comparison
Compare SMG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMG | TNGX |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SMG | TNGX |
|---|---|---|
| Price | $59.66 | $23.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $73.00 | $21.78 |
| AVG Volume (30 Days) | 946.9K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 504.92 | 26.89 |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $3,016,500,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $31.03 | ★ N/A |
| Revenue Growth | 6.17 | ★ 48.29 |
| 52 Week Low | $52.00 | $1.91 |
| 52 Week High | $72.35 | $28.41 |
Technical Indicators
Market Signals| Indicator | SMG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 52.76 |
| Support Level | $58.60 | $20.76 |
| Resistance Level | $64.96 | $28.41 |
| Average True Range (ATR) | 2.72 | 1.66 |
| MACD | -0.39 | -0.36 |
| Stochastic Oscillator | 18.14 | 42.18 |
Price Performance
Historical ComparisonAbout SMG Scotts Miracle-Gro Company (The)
Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.